In context
IGF-1 LR3 is an IGF-I analogue with altered binding-protein interactions. A fetal-sheep study examined whether it promoted growth in growth-restricted animals. [1]
At a glance
- Type
- Peptide / related experimental research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- The study did not demonstrate the intended growth effect in that model. Fetal-animal experiments do not establish benefit or safety for adult human performance use.
How to interpret this evidence
The study did not demonstrate the intended growth effect in that model. Fetal-animal experiments do not establish benefit or safety for adult human performance use. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. pubmed.ncbi.nlm.nih.gov